Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ACEIs

Phase 3Small molecule

TTanta University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Angiotensin Converting EnzymeNot yet recruiting

Angiotensin Converting EnzymePhase 3

Not yet recruiting

Timeline

Expected Milestones

Q4 2029

Phase 3Not yet recruiting

Angiotensin Converting Enzyme

NCT04345406

Clinical

Trials by Indication[1]

Angiotensin Converting Enzyme1 trial

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Not yet recruiting·TTanta University·Phase 3·NCT04345406·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACEIs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACEIs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACEIs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTanta University

Related News